Article Text

Download PDFPDF

Statistics from

Vanderbilt Vaccine and Treatment Evaluation Unit to Receive $24 Million

As part of its renewal of the contract between Vanderbilt's Vaccine and Treatment Evaluation Unit (VTEU) and the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Vanderbilt University Medical Center will receive nearly $24 million from the federal government over the next 7 years to continue evaluating innovative vaccines for malaria, pandemic flu, and other infections. A portion of the funds will support development of adjuvants. Researchers at Vanderbilt are also working on cytomegalovirus (CMV) prevention and novel types of seasonal influenza vaccines. In a collaborative effort with colleagues at Stanford University, researchers are working on an innovative malaria vaccine. Vanderbilt's VTEU is 1 of 8 in the country funded by the NIH. The unit's unit's principal investigator, Kathryn Edwards, MD, has led the Vanderbilt VTEU since 2002. Beginning in the 1970's, Peter Wright, MD, Shedd Professor of Pediatric Infectious Disease, directed the unit for more than 20 years and saw the unit transformed from a small vaccine clinic serving children to a nationally significant testing center during the outbreak of swine flu in 1976. It has since become internationally prominent for its work on vaccines against respiratory syncytial virus, haemophilius influenzae, and other serious childhood infections. Serving as the basis for the establishment of Vanderbilt's HIV Vaccine Testing Unit in 1988, the VTEU is a model for rapid response to …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.